Evidence map›Paper›PMID 40490579›Full record

ArticleSurgical endoscopy2025

Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery.

Mason Friesch, Mitchel Fernando, Emma Sheedy, Irena Helenowski, Laura Wool, Monica Edwards, Kevin Brown, James Lau, Tyler Cohn

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mason FrieschStritch School of Medicine, Loyola University Chicago, 2160 S 1St Ave, Maywood, IL, USA. mfriesch@luc.edu.ORCID http://orcid.org/0009-0000-9485-3386
Mitchel FernandoStritch School of Medicine, Loyola University Chicago, 2160 S 1St Ave, Maywood, IL, USA.
Emma SheedyDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.
Irena HelenowskiDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.
Laura WoolDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.
Monica EdwardsDepartment of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Kevin BrownDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.
James LauDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.
Tyler CohnDepartment of Surgery, Loyola University Medical Center, Maywood, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for management of obesity and diabetes. In this context, we aim to determine the effect of preoperative GLP-1RA use on surgical outcomes and long-term weight loss following bariatric surgery.

methodsWe retrospectively identified diabetic patients undergoing primary bariatric surgery at an academic institution between 2014 and 2024. Patients on a GLP-1RA at the time of surgery were compared with GLP-1RA naive patients. Pearson's chi-squared and Fisher's exact tests were used where appropriate to compare the differences in baseline characteristics. A 1:1 nearest neighbor propensity match was used to assess the differences in postoperative outcomes. Mixed-effects models were created to account for repeated weight measures postoperatively with the interactions of GLP-1RA therapy on percent total body weight loss (%TBWL). These models were adjusted for procedure type, patient age, sex, and race.

results323 patients met the inclusion criteria. 132 (40.9%) patients were on a GLP-1RA at the time of their procedure while 191 (59.1%) were not. On univariate comparison, GLP-1RA naive patients were less likely to have hyperlipidemia (57% v 69%, p = 0.03) and more likely to undergo RYGB than GLP-1RA patients (84.82% vs 62.88%, p < 0.001). There were no differences in any 30-day postoperative outcomes. GLP-1RA naive patients had better weight loss at one year postoperatively than GLP-1RA patients (TBWL 24.1% vs 20.5%, p = .003). As the follow-up period extended, the weight loss between the groups became more similar. At 5 years postoperatively, the GLP-1RA naive patients had 19.8% TBWL vs. 19.4% TBWL in the GLP-1RA group (p = 0.80).

conclusionsPreoperative GLP-1RA use is safe prior to bariatric surgery but is associated with inferior early postoperative weight loss in diabetic patients. GLP-1RA naive patients appear to experience greater weight recidivism when compared to patients on a GLP-1RA prior to surgery, resulting in comparable long-term weight loss.

Indexed as

Bariatric SurgeryDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesity, MorbidPreoperative CareWeight LossAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsBariatric surgeryGLP-1 agonistsOutcomes

Identifiers

PMID40490579

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.